Michal Ayalon, PHD

Dr. Ayalon serves as our Vice President of Research & Development since February 2019.

Dr. Ayalon has nearly 20 years of experience in drug discovery and drug development, as a senior biopharmaceuticals executive.  Prior to joining Kamada, Dr. Ayalon served as Head of R&D at 89bio Ltd., where she led the overall development strategy of the company and managed all R&D functions, including medical, clinical, pre-clinical, CMC, regulatory, and project management. Previously, Dr. Ayalon was a Project Champion at Teva Pharmaceutical Industries Ltd.. She was also Vice President of Research & Development at Galmed Pharmaceuticals Ltd.. Prior to this, Dr. Ayalon held various R&D positions in biopharmaceutical companies.

Dr. Ayalon holds a Ph.D. in cell biology from Tel-Aviv University, and holds a PostDoc in Molecular Biology of the Cell from the Weizmann Institute of Science.